Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey
Ou, S.H.I. (University of California Irvine School of Medicine. Chao Family Comprehensive Cancer Center)
Le, X. (University of Texas MD Anderson Cancer Center)
Nagasaka, M. (University of California Irvine School of Medicine. Chao Family Comprehensive Cancer Center)
Reungwetwattana, Thanyanan (Mahidol University)
Ahn, M.J. (Department of Hematology and Oncology. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Lim, D.W.T. (Duke-NUS School of medicine. National Cancer Center)
Santos, E.S. (Charles E. Schmidt College of Medicine. Florida Atlantic University)
Shum, E. (NYU Langone Perlmutter Cancer Center)
Lau, S.C.M. (NYU Langone Perlmutter Cancer Center)
Lee, J.B. (Yonsei Cancer Center Yonsei University)
Calles, A. (Hospital General Universitario Gregorio Marañón)
Wu, F. (Shanghai Chest hospital. Tongji University School of Medicine)
Lopes, G. (Department of Medicine. Division of Medical Oncology. Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine)
Sriuranpong, V. (Chulalongkorn University. King Chulalongkorn Memorial Hospital)
Tanizaki, J. (Department of Medicine. Kindai University School of Medicine)
Horinouchi, H. (Department of Thoracic Oncology. National Cancer Center Hospital Tokyo)
Garassino, M.C. (Department of Medicine. Division of Medical Oncology-Hematology. University of Chicago Medicine)
Popat, S. (Royal Marsden Hospital. London. Imperial College)
Besse, B. (Paris-Saclay University)
Rosell, Rafael (Department of Hematology-Oncology. National University Cancer Institute. National University Hospital)
Soo, Ross A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	The year 2024 is the 20 anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential "cure" in early-stage EGFR+ NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most EGFR+ NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described "discoveries" of activating EGFR mutations (del19, L858R, exon 20 insertions, and "uncommon" mutations) were published. To commemorate this 20 anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered "honorable mention" and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as "syllabus" for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25 anniversay of the discovery EGFR mutations (i. e. top 25 papers on the 25 years since the discovery of activating EGFR mutations).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	20th anniversary ; EGFR mutations ; NSCLC ; Expert panel ; Top 20 papers
Publicat a:	Lung Cancer: Targets and Therapy, Vol. 15 (2024) , p. 87-114, ISSN 1179-2728

DOI: 10.2147/LCTT.S463429
PMID: 38938224

28 p, 836.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats